Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa is an experimental angiotensin IV analogue studied in rodents for effects on the hepatocyte growth factor (HGF) / c-Met system in the brain.
Regulatory status: Not a medicine. No human trial has been published, it is not approved anywhere, and it is sold only as a research chemical.
Default vial
10 mg
Default mix
2 mL
Reported range
No published human dose
Draw (U-100)
20 u
An angiotensin IV analogue acting on the HGF/c-Met system, studied in rodents and cell culture. No human trial has been published, so no dose is established.
Where these numbers come from
No published study reports a dose for this compound in people. The figures here exist only so the calculator can run — they are not a recommendation. The published Dihexa work is rodent and cell-culture research.
- AngIV-analog Dihexa rescues cognitive impairment in the APP/PS1 mouse, Brain Sci 2021
- Effects of an angiotensin IV analog on 3-nitropropionic acid-induced Huntington's-like symptoms in rats, J Huntingtons Dis 2024
Reviewed October 2026
What it is
- A small synthetic molecule derived from angiotensin IV, modified with a hexanoic acid group to resist breakdown and cross into the brain.
- Described by its developers as an HGF/c-Met activator rather than a receptor agonist in the usual sense.
- Studied in rodents by oral and injected routes; no human route or schedule is established.
- A research compound, not a therapy.
How it is described to act
- 1
In animal studies it is given orally or by injection and is reported to reach the brain, which was the point of the chemical modification.
- 2
Reported to act on the HGF/c-Met system, which is involved in synapse formation.
- 3
Investigators propose it promotes synaptogenesis; this is the hypothesis the animal work was designed to test.
- 4
In rodent cognition models this was associated with improved performance on learning and memory tasks.
What the research has looked at
Rodent cognition studies
- In the APP/PS1 Alzheimer's mouse model, researchers reported Dihexa improved cognitive measures, attributing the effect to PI3K/AKT signalling (Brain Sci, 2021).
- In a rat model of Huntington-like injury induced by 3-nitropropionic acid, investigators reported effects of an angiotensin IV analogue on the resulting symptoms (J Huntingtons Dis, 2024).
Other preclinical work
- In zebrafish lateral line hair cells, an HGF mimetic including Dihexa was reported to protect against aminoglycoside damage (Front Cell Neurosci, 2015).
- Dihexa also appears as one component of small-molecule protocols for differentiating stem cells in vitro, which is a laboratory use rather than a therapeutic finding.
Strength of evidence: Preclinical evidence only
All published work is in rodents, fish or cell culture. No human has taken this compound in a published study.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- There is no human safety data.
- The HGF/c-Met pathway it targets is also implicated in tumour growth and metastasis. No published study has assessed what sustained activation does over time in a person.
- No published work establishes a safe dose, a safe duration, or what happens on stopping.
References
- 1.AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway, Brain Sci (2021)
- 2.Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats, J Huntingtons Dis (2024)
- 3.Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure, Front Cell Neurosci (2015)
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
Dihexa questions people ask
How do you reconstitute Dihexa?
A common starting point for a 10 mg vial of Dihexa is 2 mL of bacteriostatic water, which gives 5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of Dihexa is one dose?
At 5 mg per mL, that works out to about 20 units on a U-100 insulin syringe for a 1000 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for Dihexa?
Published and community sources describe No published human dose, oral or subcutaneous, every day, typically run 4 weeks on and 2 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should Dihexa be stored?
Lyophilized Dihexa vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.